Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: The EUROPA trial

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 6, 2007, Pages 1037-1046

  Ferrari, Roberto ^a   Bertrand, Michel E ^b   Remme, Willem J ^c   Simoons, Maarten L ^d   Deckers, Jaap W ^d   Fox, Kim M ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b Sticares Cardiovascular Research Institute ^*  (France)

^c Sticares Cardiovascular Research Foundation   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

ACE inhibition; Cardiovascular risk; EUROPA; Left venticular function; Perindopril; PERTINENT; Stable coronary artery disease; Vascular protection

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG DOSE TITRATION; DRUG EFFICACY; ENDOTHELIUM LESION; HEART ARREST; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; RESUSCITATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEART ARREST; HEART FAILURE; HUMANS; MALE; MYOCARDIAL INFARCTION; PERINDOPRIL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 37349100507     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.6.1037     Document Type: Review

References (31)

1. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur. Heart J 27, 1341-1381 (2006).
2. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur. Heart J. 28, 1598-1660 (2007).
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
4. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
5. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
6. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368, 581-588 (2006).
7. Fox K, Ferrari R, Yusuf S, Borer JS. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function? Eur. Heart J. 27, 2154-2157 (2006).
8. Gomma AH, Fox KM. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc. Drugs Ther. 15, 169-179 (2001).
9. Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int. J. Cardiol. 121, 57-61 (2007).
10. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 73, 237-246 (2007).
11. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart J. 26, 1369-1378 (2005).
12. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur. Heart J. 27, 796-801 (2006).
13. Fox KM, Bertrand ME, Remme WJ, Ferrari R, Simoons ML, Deckers JW. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am. Heart J. 153, 629-635 (2007).
14. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial. Cardiovasc. Drugs Ther. 21, 269-279 (2007).
15. Rodriguez-Granillo GA, Vos J, Bruining N et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am. J. Cardiol. 100, 159-163 (2007).
16. Rodriguez-Granillo GA, De Winter S, Bruining N et al. Effect of perindoprin on coronary remodelling: insights from a multicentre, randomized study. Eur. Heart J. 28, 2326-2331 (2007).
17. Pitt B, O'Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol. 87, 1058-1063 (2001).
18. Yusuf S, Pogue J, Myers MG et al. ACE inhibition in stable coronary artery disease. N. Engl. J. Med. 352, 937-939 (2005).
19. Fox KM. Management of coronary artery disease: Implications of the EUROPA3 trial. Br. J. Cardiol. 11, 195-204 (2004).
20. Curran MP, McCormack PL, Simpson D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs 66, 235-255 (2006)
21. PERTINENT-perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc. Drugs Ther. 17, 83-91 (2003).
22. Valgimigli M, Agnoletti L, Curello S et al. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. Circulation 107, 264-270 (2003).
23. Comini L, Bachetti T, Cargnoni A et al. Therapeutic modulation of the nitric oxide pathway: are all ACE inhibitors equivalent? Pharmacol Res 56, 42-48 (2007).
24. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. (2007) (In press).
25. Ceconi C, Francolini G, Bastianon D et al. Differences in the effec of angiotensin-converting enzyme inhibitors on the rare of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc. Drugs Ther. (2007) (In press).
26. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovasc. Ther. 3, 15-29 (2005).
27. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115, 2761-2788 (2007).
28. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575-1581 (2000).
29. Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007).
30. Hochman JS, Steg PG. Does preventive PCI work? N. Engl. J. Med. 356, 1572-1574 (2007).
31. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with β-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27, 1153-1158 (2006).